Compare BNL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | ACAD |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.4B |
| IPO Year | 2008 | 2000 |
| Metric | BNL | ACAD |
|---|---|---|
| Price | $17.39 | $19.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $23.60 | ★ $30.53 |
| AVG Volume (30 Days) | 1.9M | ★ 2.1M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.24 | 0.20 |
| Revenue | $454,138,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $8.13 | $18.71 |
| Revenue Next Year | $9.56 | $12.44 |
| P/E Ratio | ★ $73.02 | $101.40 |
| Revenue Growth | 5.17 | ★ 40.45 |
| 52 Week Low | $17.13 | $18.39 |
| 52 Week High | $23.10 | $30.96 |
| Indicator | BNL | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 36.18 |
| Support Level | N/A | $18.39 |
| Resistance Level | $18.81 | $22.92 |
| Average True Range (ATR) | 0.44 | 0.59 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 14.48 | 61.01 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.